New Hope For A Previously Diagnosed Disease

Weber Shandwick MENAT and Pfizer

According to WHO, in most countries where sickle-cell anemia is a major public health concern, its management has remained inadequate. Sickle Cell Disease (SCD) can cause chronic anemia and spleen disorders, leading to severe complications and even death, particularly in children under seven. In the GCC, with SCD prevalence rates up to 5.8 percent, there is a gap in awareness and media focus on such rare diseases, leaving patients and their families without adequate support and understanding. <br />To bridge this critical gap, Pfizer initiated the Sickle Cell Health Awareness, Perspectives, and Experiences (SHAPE) survey shedding light on the profound impact of SCD on patients and caregivers. Operating with a modest budget, Weber Shandwick leveraged these insights to spearhead a media roundtable in Oman, generating significant media coverage and successfully positioning Pfizer as a proactive leader in addressing SCD, transforming it from a neglected issue into a top regional health priority.